Last reviewed · How we verify

Peg-IFN + WB RBV for 24 weeks

National Taiwan University Hospital · FDA-approved active Small molecule

Pegylated interferon alpha combined with weight-based ribavirin stimulates the immune system to inhibit hepatitis C virus replication and clearance.

Pegylated interferon alpha combined with weight-based ribavirin stimulates the immune system to inhibit hepatitis C virus replication and clearance. Used for Chronic hepatitis C virus infection (genotype 2 and 3), Chronic hepatitis C virus infection (select genotype 1 patients).

At a glance

Generic namePeg-IFN + WB RBV for 24 weeks
Also known asPegasys plus Copegus
SponsorNational Taiwan University Hospital
Drug classImmunomodulator + nucleoside analog antiviral combination
TargetInterferon-alpha receptor (IFNAR); HCV RNA-dependent RNA polymerase
ModalitySmall molecule
Therapeutic areaVirology / Hepatology
PhaseFDA-approved

Mechanism of action

Pegylated interferon-alpha (Peg-IFN) is a long-acting immunomodulator that activates innate and adaptive immune responses against HCV, while ribavirin (RBV) is a nucleoside analog that directly inhibits viral RNA synthesis. The combination enhances viral suppression and increases sustained virological response rates. This 24-week regimen was a standard-of-care treatment for chronic hepatitis C, particularly in genotype 2/3 patients.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: